Gene Therapy in Cardiovascular Genetics

A special issue of Cardiogenetics (ISSN 2035-8148). This special issue belongs to the section "Cardiovascular Genetics in Clinical Practice".

Deadline for manuscript submissions: 30 April 2026 | Viewed by 991

Special Issue Editors


E-Mail Website
Guest Editor
Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN 46202, USA
Interests: cardiovascular genetics; genetics of cardiomyopathies; genetics of arrhythmias; molecular genetics
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Centro Cardiologico Monzino, Milan, Italy
Interests: ventricular arrhythmias; sudden cardiac death (SCD); basic science
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Genetic research in the cardiovascular field has come a long way and has brought critical knowledge about the molecular basis and mechanisms of diseases such as cardiomyopathy arrhythmias and skeletal myopathies/dystrophies with cardiac involvement. This wealth of information has led to the development of novel therapeutic interventions, which are tailored for specific molecular changes, such as variants in the LMNA, MYBPC3, TTN, and GLA genes, among others (https://www.clinicaltrials.gov/search?cond=Cardiomyopathy&intr=gene%20therapy), thus making specific genetic information both a diagnostic tool and a pre-requisite to enter ongoing clinical trials or be the recipient of approved gene therapy. In this issue, we will explore how genetic information has shaped the current clinical landscape, modifying patient management and leading to more customized interventions such as gene and targeted drug therapies.

Dr. Matteo Vatta
Dr. Valeria Novelli
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cardiogenetics is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cardiovascular genetics
  • gene therapy
  • pharmacological targets

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 419 KiB  
Article
Medical Therapy Versus Percutaneous Coronary Intervention in Patients with Myocardial Bridging from a National Population-Based Cohort Study: The Use of Big Data Analytics
by Chayakrit Krittanawong, Song Peng Ang, Fernando Alexis Padilla, Yusuf Kamran Qadeer, Zhen Wang, Nicola Gaibazzi, Samin K. Sharma, Carl J. Lavie, Hartzell V. Schaff and Ernst R. Schwarz
Cardiogenetics 2025, 15(2), 10; https://doi.org/10.3390/cardiogenetics15020010 - 9 Apr 2025
Viewed by 192
Abstract
Myocardial Bridging (MB) is typically a benign congenital coronary anomaly. MB can infrequently result in complications such as myocardial ischemia, arrhythmias, and sudden cardiac death. Recent studies suggest an underlying genetic component for MB involving DES, FBN1, SCN2B, or NOTCH1 [...] Read more.
Myocardial Bridging (MB) is typically a benign congenital coronary anomaly. MB can infrequently result in complications such as myocardial ischemia, arrhythmias, and sudden cardiac death. Recent studies suggest an underlying genetic component for MB involving DES, FBN1, SCN2B, or NOTCH1. The role of percutaneous coronary intervention (PCI) in managing MB, compared to optimal medical therapy (OMT), remains uncertain. Our study used the National Inpatient Sample (NIS) Database to identify patients aged 18 or older with myocardial bridging who were managed with PCI versus medical therapy. We compared the outcomes between both groups including in-hospital mortality, the trend of management of MB and other in-hospital outcomes or complications. Our results showed no statistically significant difference between both subgroups when comparing in-hospital mortality and secondary outcomes of cardiac arrest and the development of an acute kidney injury (AKI). Patients with myocardial bridging treated with PCI had a higher risk of developing cardiogenic shock, requiring LVAD, and requiring the use of intra-aortic balloon pump (IABP) compared to the medical therapy subgroup. Our study suggests the decision to perform PCI in myocardial bridging patients should be individualized such as in patients with refractory symptoms despite medical therapy or those with known high-risk features. Full article
(This article belongs to the Special Issue Gene Therapy in Cardiovascular Genetics)
Show Figures

Figure 1

Back to TopTop